Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Dollar Tree’s Withering Prospects

By Will Ashworth, InvestorPlace Contributor

Dollar Tree's buyback program and the timing of its expansion plans suggest its best days are behind it.

Where Foot Locker Lost Its Footing

By Will Ashworth, InvestorPlace Contributor

A close look at Foot Locker reveals signs of stock-performance fatigue.

Luxury Stock Tiffany Is Way Overpriced

By Will Ashworth, InvestorPlace Contributor

Tiffany NYSE:TIF is a luxury stock that is overpriced in this weak consumer spending environment.

Why You Shouldn’t Drink the PepsiCo Punch

By Will Ashworth, InvestorPlace Contributor

PEP may have a squeaky clean exterior, but here are some reasons you may want to think twice about owning the stock.

Kroger Investors Should Switch Grocers

By Will Ashworth, InvestorPlace Contributor

Free cash flow and valuation reveal this other supermarket as a solid substitute for Kroger stockholders.

Don’t Wait Through Kraft’s Drawn-Out Split

By Will Ashworth, InvestorPlace Contributor

Even if Kraft's proposed spinoff works, it could be years before it's reflected in a significant stock price jump.

It May Be Time to Lose Discover Financial Shares

By Will Ashworth, InvestorPlace Contributor

After its spinoff by Morgan Stanley, Discover Financial has outperformed its parent, but MS stock is better poised to grow.

Procter & Gamble Hard to Appreciate

By Will Ashworth, InvestorPlace Contributor

Procter & Gamble's dividend income is considerable, but equity investors should beware this company's capital appreciation.

What Ails UnitedHealth

By Will Ashworth, InvestorPlace Contributor

Share repurchases, meager dividends, low margins and pending regulations cloud prospects for UnitedHealth Group's stock.

Sell While CBS’ Star Is Still Bright

By Will Ashworth, InvestorPlace Contributor

The media outlet's numbers aren't all pristine, and the potential leadership fallout should Redstone suddenly pass away is a legitimate concern.

Load More